Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer…
An 8-year update from the Phase III ADAURA trial revealed that adjuvant osimertinib continues to offer an 8-year overall survival advantage for resected EGFR-mutated non-small cell lung cancer (NSCLC) patients. In the study, 682 patients with completely resected EGFR-mutated stage IB–IIIA NSCLC were randomly assigned to receive osimertinib 80 mg daily or placebo for up to 3 years.
The results, published in the Journal of Thoracic Oncology, showed that patients on osimertinib had a 79% overall survival rate compared to 64% in the placebo group, a 15-percentage-point difference. The hazard ratio for overall survival was 0.52 (95% CI, 0.39–0.71), indicating a 52% reduction in the risk of death with osimertinib.
The survival benefit was observed across predefined subgroups and persisted even when considering adjuvant chemotherapy.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
